This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The following outcomes were assessed from an ad hoc review of the literature: the percentages of patients with various heart lesions in the cohort; the probability of hospitalisation for RSV among paediatric patients who did and did not receive palivizumab prophylaxis;
the length of hospital stay for patients who did and did not receive palivizumab prophylaxis; and the number of days in an intensive care unit (ICU) for patients who did and did not receive palivizumab prophylaxis.
Study designs and other criteria for inclusion in the review
Most of the parameter estimates were taken from a single multi-centre placebo-controlled trial (Feltes et al. 2003 , see 'Other Publications of Related Interest' below for bibliographic details). The authors also referred to a population-based study and census data for the derivation of an estimate of disease prevalence (Botto et al. 2001 , see 'Other Publications of Related Interest' below for bibliographic details). The remaining 6 data sources were not described.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The values for the parameters in the model were obtained from 9 published studies and reports.
Methods of combining primary studies
In general, the primary studies were not combined.
Investigation of differences between primary studies
Results of the review
The following parameters were used in the model. The probability of hospitalisation was 5.3% for patients who received palivizumab prophylaxis and 9.7% for those who did not.
The length of hospital stay was 10.7 days for patients who received palivizumab prophylaxis and 13.3 days for those who did not.
The number of days in the ICU was 15.9 days per 100 children who received palivizumab prophylaxis and 71.2 days per 100 children who did not.
Methods used to derive estimates of effectiveness
The authors made some assumptions in their model, which supplemented the data derived from the literature.
Estimates of effectiveness and key assumptions
For patients with ventricular septal defect, only 25% would have a haemodynamically significant lesion.
The mortality rate for patients who were admitted to the hospital would be 3% whether they had received palivizumab or not.
By reducing the hospital admission rate for RSV bronchiolitis, palivizumab would result in a 0.13% reduction in overall mortality.
The average life expectancy of infants in the cohort was 77.2 years, based on the US average life expectancy in 2002.
Measure of benefits used in the economic analysis
The measures of health benefit used were the life-years saved (LYS) and quality-adjusted life-years (QALYs) saved. These were derived from the model and were discounted at an annual rate of 3%. The utility value of adult congestive heart failure (CHF) patients was used as a proxy for CHD lesions that resulted in long-term exercise limitations. Healthrelated quality of life scores for adults with CHF were obtained from a single published study (Fryback et al. 1993 , see 'Other Publications of Related Interest' below for bibliographic details) that assessed utility using the time trade-off method. The utility value of adult CHF patients was 0.71. The model assumed that CHD patients with lesions that were not associated with long-term exercise limitation had a utility value of 1.0.
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination
Copyright © 2017 University of York Page: 3 / 7
The model also estimated the number of RSV-related deaths averted per 5,000 patients.
Direct costs
The direct costs of health care and the direct costs to the patients' parents were included in the analysis. The costs included were for palivizumab and its administration, ICU and non-ICU hospital care, and the parents' travel costs associated with administration of the prophylaxis. Overhead allocation and office staff time were considered to be negligible and, hence, were not included in the analysis. The drug costs came from average wholesale prices, while drug administration costs were based on physician and nursing mean hourly wages estimated from US Department of Labor sources. The costs of hospitalisation were derived from a published analysis of bronchiolitis hospitalisation costs from a consortium of 10 children's hospitals and were compared with data from published literature. Travel costs were calculated from the Internal Revenue Service mileage reimbursement rate.
The cost estimates were reported separately from other model parameters. Discounting was applied at a rate of 3%. The costs were adjusted to 2002 prices, although the method used was not reported. The total costs were derived using modelling.
Statistical analysis of costs
The costs were treated deterministically. No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were included, which was appropriate given the study perspective. The indirect costs reported were the productivity losses incurred by the parent as a consequence of attending appointments for the administration of prophylaxis, or for staying with the infant during periods of hospitalisation. The number of work days lost and the value of each day were reported separately. The number of work days lost was based on the number of days of hospitalisation, which was taken from a published study. The value of a work day was based on the average wage, as reported by the US Bureau of Labor and Statistics 2002. Discounting was applied at a rate of 3%.
Currency
US dollars ($).
Sensitivity analysis
A sensitivity analysis was conducted to investigate the robustness of the results under the uncertainty surrounding the parameters of the model. The methods used were not described. However, it is likely that one-way sensitivity analyses were undertaken. The authors did not justify the ranges over which the variables were tested. The ranges appear to have been based on their assumptions rather than being derived from the literature. The parameters investigated were the RSV-related hospital mortality rate, the utility value for CHD lesions that resulted in long-term exercise limitation, and a differential reduction in hospital mortality between patients who received prophylaxis and those who did not.
